These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 19515614)
1. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Vermeulen J; De Preter K; Naranjo A; Vercruysse L; Van Roy N; Hellemans J; Swerts K; Bravo S; Scaruffi P; Tonini GP; De Bernardi B; Noguera R; Piqueras M; Cañete A; Castel V; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Michon J; Combaret V; Fischer M; Oberthuer A; Ambros PF; Beiske K; Bénard J; Marques B; Rubie H; Kohler J; Pötschger U; Ladenstein R; Hogarty MD; McGrady P; London WB; Laureys G; Speleman F; Vandesompele J Lancet Oncol; 2009 Jul; 10(7):663-71. PubMed ID: 19515614 [TBL] [Abstract][Full Text] [Related]
2. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. De Preter K; Mestdagh P; Vermeulen J; Zeka F; Naranjo A; Bray I; Castel V; Chen C; Drozynska E; Eggert A; Hogarty MD; Izycka-Swieszewska E; London WB; Noguera R; Piqueras M; Bryan K; Schowe B; van Sluis P; Molenaar JJ; Schramm A; Schulte JH; Stallings RL; Versteeg R; Laureys G; Van Roy N; Speleman F; Vandesompele J Clin Cancer Res; 2011 Dec; 17(24):7684-92. PubMed ID: 22031095 [TBL] [Abstract][Full Text] [Related]
3. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
5. A signature of 29 immune-related genes pairs to predict prognosis in patients with neuroblastoma. Song J; Zhao Q; Xu Y; Zhu L Int Immunopharmacol; 2020 Nov; 88():106994. PubMed ID: 33182060 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Liu N; Chen NY; Cui RX; Li WF; Li Y; Wei RR; Zhang MY; Sun Y; Huang BJ; Chen M; He QM; Jiang N; Chen L; Cho WC; Yun JP; Zeng J; Liu LZ; Li L; Guo Y; Wang HY; Ma J Lancet Oncol; 2012 Jun; 13(6):633-41. PubMed ID: 22560814 [TBL] [Abstract][Full Text] [Related]
7. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. Sokol E; Desai AV; Applebaum MA; Valteau-Couanet D; Park JR; Pearson ADJ; Schleiermacher G; Irwin MS; Hogarty M; Naranjo A; Volchenboum S; Cohn SL; London WB J Clin Oncol; 2020 Jun; 38(17):1906-1918. PubMed ID: 32315273 [TBL] [Abstract][Full Text] [Related]
8. Identification of prognostic long noncoding RNAs associated with spontaneous regression of neuroblastoma. Meng X; Fang E; Zhao X; Feng J Cancer Med; 2020 Jun; 9(11):3800-3815. PubMed ID: 32216054 [TBL] [Abstract][Full Text] [Related]
9. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724 [TBL] [Abstract][Full Text] [Related]
10. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. Yanik GA; Parisi MT; Naranjo A; Nadel H; Gelfand MJ; Park JR; Ladenstein RL; Poetschger U; Boubaker A; Valteau-Couanet D; Lambert B; Castellani MR; Bar-Sever Z; Oudoux A; Kaminska A; Kreissman SG; Shulkin BL; Matthay KK J Nucl Med; 2018 Mar; 59(3):502-508. PubMed ID: 28887399 [TBL] [Abstract][Full Text] [Related]
11. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients. Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155 [TBL] [Abstract][Full Text] [Related]
12. Integration of clinical characteristics and molecular signatures of the tumor microenvironment to predict the prognosis of neuroblastoma. Cheng H; Zhang L; Yang S; Ren Q; Chang S; Jin Y; Mou W; Qin H; Yang W; Zhang X; Zhang W; Wang H J Mol Med (Berl); 2023 Nov; 101(11):1421-1436. PubMed ID: 37712965 [TBL] [Abstract][Full Text] [Related]
13. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment. Rosswog C; Schmidt R; Oberthuer A; Juraeva D; Brors B; Engesser A; Kahlert Y; Volland R; Bartenhagen C; Simon T; Berthold F; Hero B; Faldum A; Fischer M Neoplasia; 2017 Dec; 19(12):982-990. PubMed ID: 29091799 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382 [TBL] [Abstract][Full Text] [Related]
15. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers. Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397 [TBL] [Abstract][Full Text] [Related]
16. Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system. Stricker TP; Morales La Madrid A; Chlenski A; Guerrero L; Salwen HR; Gosiengfiao Y; Perlman EJ; Furman W; Bahrami A; Shohet JM; Zage PE; Hicks MJ; Shimada H; Suganuma R; Park JR; So S; London WB; Pytel P; Maclean KH; Cohn SL Mol Oncol; 2014 May; 8(3):669-78. PubMed ID: 24560446 [TBL] [Abstract][Full Text] [Related]
17. Development and validation of a 21-gene prognostic signature in neuroblastoma. Gupta M; Kannappan S; Jain M; Douglass D; Shah R; Bose P; Narendran A Sci Rep; 2023 Aug; 13(1):12526. PubMed ID: 37532697 [TBL] [Abstract][Full Text] [Related]
18. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Fischer M; Oberthuer A; Brors B; Kahlert Y; Skowron M; Voth H; Warnat P; Ernestus K; Hero B; Berthold F Clin Cancer Res; 2006 Sep; 12(17):5118-28. PubMed ID: 16951229 [TBL] [Abstract][Full Text] [Related]
19. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer. Li B; Cui Y; Diehn M; Li R JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838 [TBL] [Abstract][Full Text] [Related]
20. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. De Preter K; Vermeulen J; Brors B; Delattre O; Eggert A; Fischer M; Janoueix-Lerosey I; Lavarino C; Maris JM; Mora J; Nakagawara A; Oberthuer A; Ohira M; Schleiermacher G; Schramm A; Schulte JH; Wang Q; Westermann F; Speleman F; Vandesompele J Clin Cancer Res; 2010 Mar; 16(5):1532-41. PubMed ID: 20179214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]